Carisbamate RWJ-333369|cas:194085-75-1|西域试剂

Carisbamate RWJ-333369,99.77%

产品编号：Bellancom-14948| CAS NO：194085-75-1| 分子式：C₉H₁₀ClNO₃| 分子量：215.63

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14948	￥2500.00	杭州北京（现货）
Bellancom-14948	￥4000.00	杭州北京（现货）
Bellancom-14948	￥8500.00	杭州北京（现货）
Bellancom-14948	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Carisbamate RWJ-333369

产品介绍

Carisbamate (RWJ-333369) 是一种口服有效的神经调节剂。Carisbamate 能防止癫痫样放电的发展和产生，在体外癫痫样损伤后具有神经保护作用。Carisbamate 在全身性惊厥性和非惊厥性癫痫的遗传模型中具有较好的抗癫痫活性。

生物活性

Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy.

体外研究

Carisbamate (200 µM; 12 h) exhibits antiepileptic effects on SREDs model of hippocampal cells.
Carisbamate (200 µM; 24 h) shows long lasting effects on the hippocampal neurons that are independent from antiepileptic effects in vitro.
Carisbamate not only inhibits the development and expression of SREDs in the majority of neurons, but also decreases seizure frequency and duration in the few neurons that still has an occasional epileptiform event.
Carisbamate (200 µM) shows neuroprotective effects on hippocampal cells with SE (status epilepticus)-like injury.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Hippocampal cells (from 2-day postnatal Sprague-Dawley rat; spontaneous recurrent epileptiform discharges (SREDs) model)
Concentration:	200 µM
Incubation Time:	12 h
Result:	Acutely inhibited SREDs with greater than 95% of the neurons exhibited an in vitro antiepileptic effect.

Cell Viability Assay

Cell Line:	Hippocampal cells (SREDs model)
Concentration:	200 µM
Incubation Time:	24 h
Result:	Exhibited cells evaluated the day after treatment were still free of in vitro seizure activity and did not develop SREDs.

体内研究
(In Vivo)

Carisbamate (10, 30, 60 mg/kg; i.p.; single) dose dependently reduces the expression of spike-and-wave discharges (SWD) in absence seizures rat model.
Carisbamate (20, 30 mg/kg; i.p.; single) shows no wild running episode or tonic seizure occurres in any of the rats tested.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male genetic absence epilepsy rat (absence seizures model).
Dosage:	10, 30, 60 mg/kg
Administration:	Intraperitoneal injection; single.
Result:	Completely inhibited SWD when at 60 mg/kg after 120 min, and restored the duration of SWD to the control level when at 30 mg/kg after 100 min.

Animal Model:	Male Wistar audiogenic sensitive rat (convulsive seizures model).
Dosage:	10, 20, 30 mg/kg
Administration:	Intraperitoneal injection; single.
Result:	Showed no wild running episode or tonic seizure occurred in any of the rats tested when at 20 and 30 mg/kg. Increased by 327% the latency to the tonic seizure that still occurred in the six of eight rats studied when at 10 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male genetic absence epilepsy rat (absence seizures model).
Dosage:	10, 30, 60 mg/kg
Administration:	Intraperitoneal injection; single.
Result:	Completely inhibited SWD when at 60 mg/kg after 120 min, and restored the duration of SWD to the control level when at 30 mg/kg after 100 min.

Animal Model:	Male Wistar audiogenic sensitive rat (convulsive seizures model).
Dosage:	10, 20, 30 mg/kg
Administration:	Intraperitoneal injection; single.
Result:	Showed no wild running episode or tonic seizure occurred in any of the rats tested when at 20 and 30 mg/kg. Increased by 327% the latency to the tonic seizure that still occurred in the six of eight rats studied when at 10 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male genetic absence epilepsy rat (absence seizures model).
Dosage:	10, 30, 60 mg/kg
Administration:	Intraperitoneal injection; single.
Result:	Completely inhibited SWD when at 60 mg/kg after 120 min, and restored the duration of SWD to the control level when at 30 mg/kg after 100 min.

Animal Model:	Male Wistar audiogenic sensitive rat (convulsive seizures model).
Dosage:	10, 20, 30 mg/kg
Administration:	Intraperitoneal injection; single.
Result:	Showed no wild running episode or tonic seizure occurred in any of the rats tested when at 20 and 30 mg/kg. Increased by 327% the latency to the tonic seizure that still occurred in the six of eight rats studied when at 10 mg/kg.